MedTrace Logo

Identifying Biomarkers That Distinguish PTSD and mTBI Using Advanced Magnetic Resonance Spectroscopy

NCT02927288 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2018-01-18

No results posted yet for this study

Summary

The purpose of this study is to develop a new test to help diagnose mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) in soldiers. Chemicals in the brain will be measured using a Magnetic Resonance Spectroscopy (MRS) scan. In the study, the investigators will compare the information they obtain from scans of participants with mTBI, PTSD or both, to scans from healthy volunteers to understand the differences between these groups. If the results can tell the difference between participants with mTBI and PTSD, the investigators should be able to help safely diagnose patients in the future.

Conditions

  • Post-Traumatic Stress Disorders
  • Brain Injuries

Sponsors & Collaborators

  • United States Army Research Institute of Environmental Medicine

    collaborator FED

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Alexander Lin, PhD · Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02927288 on ClinicalTrials.gov